FOLH1 and neoplasm: Tissue integrity and antigenicity was determined by evaluation of the expression of nine different markers with nuclear and/or cytoplasmic localization (Ki67, AR, CK18) in addition to markers that distinguish tumor vs. benign glands (HMW-CK, p63, and P504S/AMACR) or proteins usually expressed by prostate cells (PSA, P501S and PSMA) (Fig. 2a).